June 20th 2022
Researchers believe this may be the first report of the use of topical brimonidine gel for the treatment of eyelid ptosis associated with cosmetic use of botulinum toxin.
Enjoy these CME sessions at AAO 2023
Register Now!
C.R.U. Eye Symposium (Current, Relevant, Useful)
11/10/2023-11/12/2023
Register Now!
The Ophthalmology Times EyeCon 2023
Register Now!
(CME/CNE Credit) Community Practice Connections™: Comprehensive Key Advances in Biosimilars for Retinal Diseases – Reviewing the Evidence, Addressing Patient Perspectives, and Practice Utilization for the Retina Specialist
View More
(COPE Credit) Community Practice Connections™: Comprehensive Key Advances in Biosimilars for Retinal Diseases – Reviewing the Evidence, Addressing Patient Perspectives, and Practice Utilization for the Retina Specialist
View More
Free COPE CE at AAOPT
Register Now!
Clinical Consultations: Individualizing Management of Uveitic Macular Edema - Clinical Updates in Treatment Options
View More
Community Practice Connections™: Ophthalmology and Oncology Perspectives on Integrating Novel Bispecific Antibodies Into the Uveal Melanoma Treatment Paradigm
View More
Medical Crossfire®: Ophthalmology and Oncology Perspectives on Integrating Novel Bispecific Antibodies Into the Uveal Melanoma Treatment Paradigm
View More
The Optometry Times EyeCon 2023
Register Now!
(CME Credit) Community Practice Connections™: Expert Approaches in Cataract Surgery – Managing Advances in Techniques and Technologies With an Updated Armamentarium
View More
(COPE Credit) Community Practice Connections™: Expert Approaches in Cataract Surgery – Managing Advances in Techniques and Technologies With an Updated Armamentarium
View More
(CME/CNE Credit) MGD-Associated Dry Eye Disease – How Emerging Options May Shift the Treatment Paradigm
View More
(COPE Credit) MGD-Associated Dry Eye Disease – How Emerging Options May Shift the Treatment Paradigm
View More
(COPE Credit) Expert Illustrations & Commentaries™: Envisioning New Therapies for Meibomian Gland Dysfunction-Associated DED
View More
(CME/CNE Credit) Expert Illustrations & Commentaries™: Envisioning New Therapies for Meibomian Gland Dysfunction-Associated DED
View More
(COPE Credit) Patient, Provider, and Caregiver Connection™: Individualizing Care in Allergic Conjunctivitis – Understanding the Patient’s Perspective in Alleviating Disease Burden
View More
(CME Credit) Patient, Provider, and Caregiver Connection™: Individualizing Care in Allergic Conjunctivitis – Understanding the Patient’s Perspective in Alleviating Disease Burden
View More
Expert Insights in Geographic Atrophy with Transformative Care on the Horizon – Understanding the Complement System as a Target for Treatment
View More
Community Practice Connections™: Ophthalmology Times® EyeCon 2022
View More
Shared Perspectives in Managing Presbyopia – Understanding a New Paradigm for Optimizing Quality of Life
View More
Perfecting Co-Management of Glaucoma – Utilizing Development in the Spectrum of Treatment Options
View More
Community Practice Connections™: 2nd Annual Optometry Times™ EyeCon
View More
Medical Crossfire®: Expert Perspectives in Geographic Atrophy – How Can We Prepare for a New Era of Treatment?
View More
(CME Credit) Addressing Healthcare Inequities Diabetic Retinal Vascular Disease: How Can We Address Ethnic Disparities within the Clinic?
View More
(COPE Credit) Addressing Healthcare Inequities Diabetic Retinal Vascular Disease: How Can We Address Ethnic Disparities within the Clinic?
View More
(CME/CNE Credit) Community Practice Connections™: Restoring the Surface Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
(COPE Credit) Community Practice Connections™: Restoring the Surface – Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
(CME Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(COPE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
Upper lid elevation with topical oxymetazoline 0.1%: providing a better view
September 22nd 2021Topical oxymetazoline HCL ophthalmic solution 0.1% (RVL-1201, RVL Pharmaceuticals, Inc.) has the potential to treat patients with varying degrees of severity of acquired ptosis compared with vehicle.
Read More
Considering double-organ bias in clinical trials of eyelid ptosis
September 1st 2021Investigators searched PubMed over the past 2 decades for clinical trials on eyelid ptosis using the terms blepharoptosis or upper eyelid ptosis or eyelid ptosis” and the filters “randomized controlled trial (RCT), clinical trial, and humans.”
Read More